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AbstrACt
Objective Cardiovascular disease (CVD) is one of the 
leading non-AIDS-defining causes of death among 
HIV-positive (HIV+) individuals. However, the evidence 
surrounding specific components of CVD risk remains 
inconclusive. We conducted a systematic review and 
meta-analysis to synthesise the available evidence and 
establish the risk of myocardial infarction (MI) among HIV+ 
compared with uninfected individuals. We also examined 
MI risk within subgroups of HIV+ individuals according to 
exposure to combination antiretroviral therapy (ART), ART 
class/regimen, CD4 cell count and plasma viral load (pVL) 
levels.
Design Systematic review and meta-analysis.
Data sources We searched MEDLINE, EMBASE, Cochrane 
Central Register of Controlled Trials and Cochrane 
Database of Systematic Reviews until 18 July 2018. 
Furthermore, we scanned recent HIV conference abstracts 
(CROI, IAS/AIDS) and bibliographies of relevant articles.
Eligibility criteria Original studies published after 
December 1999 and reporting comparative data relating to 
the rate of MI among HIV+ individuals were included.
Data extraction and synthesis Two reviewers working in 
duplicate, independently extracted data. Data were pooled 
using random-effects meta-analysis and reported as 
relative risk (RR) with 95% CI.
results Thirty-two of the 8130 identified records were 
included in the review. The pooled RR suggests that 
HIV+ individuals have a greater risk of MI compared with 
uninfected individuals (RR: 1.73; 95% CI 1.44 to 2.08). 
Depending on risk stratification, there was moderate 
variation according to ART uptake (RR, ART-treated=1.80; 
95% CI 1.17 to 2.77; ART-untreated HIV+ individuals: 
1.25; 95% CI 0.93 to 1.67, both relative to uninfected 
individuals). We found low CD4 count, high pVL and certain 
ART characteristics including cumulative ART exposure, 
any/cumulative use of protease inhibitors as a class, 
and exposure to specific ART drugs (eg, abacavir) to be 
importantly associated with a greater MI risk.
Conclusions Our results indicate that HIV infection, low 
CD4, high pVL, cumulative ART use in general including 
certain exposure to specific ART class/regimen are 
associated with increased risk of MI. The association with 
cumulative ART may be an index of the duration of HIV 
infection with its attendant inflammation, and not entirely 
the effect of cumulative exposure to ART per se.
PrOsPErO registration number CRD42014012977.
IntrODuCtIOn
Cardiovascular disease (CVD) is one of 
the leading non-AIDS causes of death and 
disability among people living with HIV 
in the combination antiretroviral therapy 
(ART) era.1 2 Although HIV-positive (HIV+) 
individuals are believed to be at higher risk 
of CVD compared with uninfected individ-
uals,3 4 the results and conclusions from the 
studies that have examined the nature of the 
risk of CVD, in particular myocardial infarc-
tion (MI) among HIV+ individuals have been 
conflicting. While some cohort studies have 
suggested a positive association between ART 
including specific drug (eg, abacavir) or 
drug class (eg, protease inhibitors (PIs)) use 
and MI, or CVD risk,5–9 others have not.10–12 
Furthermore, there has been a lack of agree-
ment between observational studies,8 11 13 
and randomised controlled trials (RCTs).14 15 
strengths and limitations of this study
 ► We used explicit eligibility criteria and a comprehen-
sive search strategy for this systematic review and 
meta-analysis.
 ► Adjudication of studies for eligibility and the data 
extraction were performed by two independent re-
viewers working in duplicate.
 ► This systematic review and meta-analysis analysed 
several additional drug exposure comparisons and 
clinical measures (eg, CD4 cell count, plasma viral 
load) that had not been previously examined in rela-
tion to myocardial infarction risk among HIV-positive 
individuals.
 ► Some of the meta-analyses were based on a small 
number of studies which is a limitation.
 ► Variability in the quality of the included studies may 
have influenced the results and thus the conclusions 
drawn.
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Clearly, the evidence regarding the nature of, and extent 
of the risk of MI and other CVD events among HIV+ indi-
viduals is far from uniform.
Five meta-analyses have been conducted in an attempt 
to synthesise the data on CVD risk among HIV+ indi-
viduals.16–20 These have either been limited in scope by 
assessing only the association between ART use and risk 
of CVD16; included trials that lacked MI event adjudica-
tion17; included trials where CVD events were not among 
the pre-specified outcomes of interest18; provided incom-
plete results on MI risk19; or amalgamated all CVD events 
(eg, MI, stroke) as a single outcome.20 In addition, this 
latter meta-analysis was fraught with a number of method-
ological ambiguities.21
Given these limitations, coupled with the publication 
of several new and updated study reports on the topic, 
we sought to undertake an updated systematic review and 
meta-analysis of studies assessing the risk of CVD among 
persons living with HIV. Considering the scope, diversity 
and differences in the definition,22–25 aetiology and clin-
ical picture of different CVD events,26 coupled with the 
strong body of literature related to HIV and MI and the 
ongoing debate around potential MI risk associated with 
use of specific ART medications such as abacavir, we have 
elected to focus primarily on MI as the outcome of interest 
for this meta-analysis, as it is the most widely researched 
CVD outcome among HIV+ individuals. The objective of 
our study was to estimate the risk of MI among HIV+ indi-
viduals relative to uninfected individuals. Additionally, we 
examined MI risk within subgroups of HIV+ individuals 
according to exposure to ART, ART class, specific ART 
regimen, CD4 cell count and plasma viral load (pVL) 
levels.
MEthODs
search strategy and selection criteria
The systematic review and meta-analysis was performed 
in accordance with the PRISMA statement.27 A protocol 
describing the inclusion criteria and analysis methods for 
this systematic review was specified in advance, registered 
and published at the international prospective register of 
systematic reviews (PROSPERO).28
The search strategy (see online supplementary 
appendix table 1) was developed in consultation with a 
medical librarian at Simon Fraser University, BC, Canada. 
The search terms were based on a combination of indexed 
and free-text terms reflecting clinical outcomes of interest 
to the review, and included the following keywords: ‘HIV, 
human immunodeficiency virus, acquired immunodefi-
ciency syndrome, HIV/AIDS, stroke, myocardial infarc-
tion, cardiac death, cerebrovascular disease, ischemic 
heart disease, cardiovascular disease and CVD’. These 
terms were used in combination to execute the searches, 
which were up to 18 July 2018. Using the Ovid platform, we 
searched the following electronic databases: MEDLINE, 
EMBASE, Cochrane Central Register of Controlled Trials 
and the Cochrane Database of Systematic Reviews. In 
addition, we screened the abstracts of the International 
AIDS Society conferences (AIDS 2012, 2014, 2016; IAS 
2013) and the Conference on Retroviruses and Oppor-
tunistic Infections (CROI 2014, 2015 and 2016). We 
also searched the reference lists of relevant articles and 
previous systematic reviews for additional eligible publi-
cations. Finally, we set up automatic PubMed literature 
alerts to identify any new relevant article published while 
the manuscript was under development.
We included original research published in English 
where at least one of the participant groups were indi-
viduals living with HIV, and presenting comparative data 
on the incidence of MI. We included studies in which 
results were stratified according to HIV status; CD4 cell 
count; pVL levels; ART use; or exposure to particular ART 
class or regimen. Studies involving non-human popula-
tions; children; as well as those reporting only unadjusted 
estimates, intermediate, surrogate or CVD biomarker 
outcomes were excluded (for additional information, 
see Study selection section in the online supplementary 
appendix, p1). To reflect the current context of HIV 
treatment and disease management, we selected studies 
published from the year 2000 onwards. Although both 
observational studies and RCTs were eligible for inclu-
sion, we did not include RCTs that were not designed to 
assess CVD events as a prespecified outcome to avoid bias.
Working independently and in duplicate, two reviewers 
(OE and GB) scanned the titles and abstracts of the 
retrieved records for eligibility. The full-text articles of 
potentially eligible studies were obtained and reviewed 
in greater details. Disagreements in study selection were 
resolved through discussion, and where necessary, a third 
investigator (RSH) was invited to facilitate consensus.
Data extraction and quality assessment
The same two reviewers (OE and GB) conducted data 
extraction independently using a predesigned data 
abstraction sheet. We extracted data on study descrip-
tors, sample characteristics, outcome assessment, risk esti-
mate for relevant comparisons and study quality features. 
Where necessary, we sought clarification directly from 
study authors through email contact. In cases where data 
from the same study described the same event risk in 
multiple publications, we extracted data from the most 
comprehensive report while supplementing missing 
study-level information from the others. In keeping with 
characterisations in the included studies, exposure to 
ART was categorised as any (or prior/some compared with 
none), recent (or within the preceding 6 months compared 
with not recent) and cumulative ART exposure per year of 
exposure.
The quality of the included studies was assessed 
according to risk of bias criteria based on the type of 
study design. As only observational studies were eventu-
ally included in the meta-analysis since eligible RCTs were 
not identified, we made this assessment by evaluating 
study design features of the eligible observational studies. 
Following guidelines in the Newcastle-Ottawa Scale for 
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assessing the quality of observational studies in meta-anal-
yses29 and with slight modification of the scoring system 
to simplify reporting, the risk of bias assessment was 
performed based on the adequacy of three key domains 
of the study design features namely: the group/partici-
pant selection; comparability of groups; and the expo-
sure and outcome assessments in the individual studies. 
For each of these key features, we assigned a ‘+’ (plus) 
sign when this was clearly and adequately described in 
the study, and a ‘–’ (minus) sign when it was not clearly 
described or was missing. A detailed description of the 
results of the quality assessment is available in the online 
supplementary appendix.
Patient and public involvement
No patients were involved in this study. We used data from 
published materials only.
Data analysis
We calculated the kappa statistic as a measure of the 
inter-reviewer agreement for the selection of articles 
meeting the inclusion/exclusion criteria. For interpreta-
tion, we defined a priori the interval for the kappa result 
using Landis and Koch criteria.30 For effect measure, 
we assumed the incidence rate ratio (IRR), OR and HR 
with corresponding sampling variance to be numerical 
approximate measures of the relative risk (RR) for a 
given association of interest with the underlying assump-
tion of a generally low event risk (<20%),31–36 and thus 
combined them as previously described.19 37–40 We tested 
this assumption in sensitivity analyses by performing 
separate meta-analyses where studies presenting results 
reported using a similar effect measure type were pooled. 
Given the expected variability among eligible studies, we 
pooled studies using the DerSimonian-Laird random-ef-
fects model.41 To minimise bias in our pooled estimates, 
adjusted risk estimates were not combined with unad-
justed estimates. The final set of studies that adjusted 
for confounders did not consistently adjust for the same 
set of confounders but were deemed to have sufficient 
internal validity to permit pooling. For the analysis that 
quantified the overall RR of MI associated with HIV infec-
tion, we performed a sensitivity analysis where we exam-
ined the appropriateness of the comparison group by 
repeating the meta-analysis and including two additional 
studies that involved a general population comparison 
group,42 43 as opposed to an HIV-uninfected comparison 
group. Given the limitations of the I2 statistics with obser-
vational studies and Cochran Q test when the number of 
studies is small,44 45 we assessed heterogeneity by visual 
inspection of the forest plots for overlap in the confi-
dence intervals of the individual studies, although the I2 
as a measure of the degree of heterogeneity across studies 
is reported in the forest plots for completeness. We were 
unable to perform meta-regression analyses to assess the 
potential effect of study-level covariates on the pooled 
estimate due to insufficient studies (<10),46 in each of 
the meta-analyses. Although we assessed publication bias 
by visually inspecting and testing for funnel plot asym-
metry,47 its interpretation was limited by a lack of sufficient 
number of studies per meta-analysis.48 49 A p value <0.05 
was considered statistically significant. The meta-analysis 
was conducted using the metafor package of the R statis-
tical programme V.3.3.1.50
rEsults
Of 8130 records identified through the database search, 
the final screening process yielded 64 potentially eligible 
publications on CVD outcomes, 32 of which had rele-
vant data on MI and were included in this meta-analysis 
(figure 1). Overall, there was near perfect agreement 
between reviewers on the inclusion of studies (kappa 
statistic=0.94; 95% CI 0.89 to 0.99). The included studies, 
most of which were conducted in the USA and Europe, 
were published between 2000 and 2017 and involved 
~383,471 HIV+ and > 798, 424 HIV- individuals (online 
supplementary appendix table 2: characteristics of the 
included studies; note: the number of individuals in cohorts 
with multiple publications was accessed only from one of the 
publications). The mean duration of follow-up varied 
across studies from ~1 to 20 years. All 32 publications 
were non-randomised studies and included two nested 
case–control studies,11 51 one cohort/nested case–control 
study,52 and 29 cohort studies; 15 of which were prospec-
tive studies, by design.3 7 8 13 42 53–62 Twenty-nine studies 
were published as full-text journal articles, while three 
were available as conference abstracts.
In general, the reporting and quality of the method-
ological aspects of the included studies were variable. 
Three studies did not provide sufficient information 
necessary to assess the study quality, as they were reported 
and available as conference abstract/poster.55 57 63 The 
eligibility criteria were clearly defined in the majority 
of studies (94%), description of study participants/ 
groups was sufficient (100%); however, the exposure or 
outcome was not adequately ascertained in 15 studies 
(47%)8 12 24 52 54 56 60 63–70; 1 (7%) of which was published as 
an abstract63 (see online supplementary appendix table 3: 
risk of bias in the included studies).
Meta-analysis of the risk of MI
Below, we summarise the results of the meta-analyses 
of MI risk according to the various risk stratifications 
assessed. To avoid duplication of reporting, only statisti-
cally important RR are stated in text; although both statis-
tically significant and insignificant results are presented 
in the figures (forest plots).
Risk of MI associated with HIV infection
The pooled RR from the five studies that met eligibility 
for this assessment of MI risk according to HIV serostatus 
suggests that HIV+ individuals are more likely to have 
an MI event compared with uninfected individuals (RR: 
1.73; 95% CI 1.44 to 2.08).3 52 56 69 71 In sensitivity analysis 
(online supplementary appendix figure S1) where we 
D
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Figure 1 Flow diagram of study selection. *, includes several conference abstract records captured through the database 
search; **, includes two studies involving a ‘general population’ comparison group. ART, combination antiretroviral therapy. 
CVD, cardiovascular disease.
repeated the meta-analysis and included two additional 
studies that involved a general population comparison 
group,42 43 the overall pooled RR was 1.60; 95% CI 1.38 
to 1.85. Figure 2 shows the forest plots for the association 
between HIV infection and MI risk. Two studies assessed 
the risk of MI by HIV serostatus according to whether ART 
treatment was received.60 72 Compared with uninfected 
individuals, the pooled RR of MI was significantly higher 
among HIV+ individuals on ART (RR: 1.80; 95% CI 1.17 
to 2.77), but not the ART-untreated HIV+ individuals 
(RR: 1.25; 95% CI 0.93 to 1.67).
Risk of MI associated with CD4 cell count and pVL levels
The pooled RR based on combining data from three 
studies suggests that low CD4 cell count (<200 cells/mm3) 
is associated with higher MI risk compared with CD4 ≥200 
(RR: 1.60; 95% CI 1.25 to 2.04).3 57 68 Conversely, a high 
pVL (≥100 000 copies/mL) was found to be associated 
D
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Figure 2 Forest plot of the meta-analysis of the risk of MI associated with HIV infection. ART, antiretroviral therapy.
with increased MI risk compared with pVL <100 000 (RR: 
1.45; 95% CI 1.11 to 1.90), based on the pooled results 
from two studies (figure 3).54 68
Risk of MI associated with recent ART exposure
With regards to recent treatment exposure (i.e., within the 
preceding 6 months), four eligible studies with data 
on nucleoside reverse transcriptase inhibitor (NRTI) 
exposure assessed the risk of MI associated with recent 
compared with not recent abacavir exposure.52 53 55 67 The 
pooled result from these four studies suggests that recent 
abacavir exposure is associated with increased risk of MI 
compared with not recent exposure (RR: 1.71; 95% CI 
1.39 to 2.10). Similarly, recent didanosine (RR: 1.29; 
95% CI 1.04 to 1.60),52 58 67 and lamivudine (RR: 1.50; 
95% CI 1.18 to 1.90),13 52 67 exposure is associated with 
increased risk of MI compared with not recent exposures. 
In contrast, there was no detectable association between 
recent tenofovir,52 58 67 zidovudine,13 52 67 stavudine,13 52 67 
emtricitabine52 67 and MI risk compared with not recent 
exposure (figure 4). Based on pooling data from two 
studies with data on non-nucleoside reverse transcriptase 
inhibitor (NNRTI) exposure,52 67 no association was found 
between recent efavirenz or nevirapine exposure and MI 
risk compared with not recent exposure (figure 5). Based 
on pooled results from the studies assessing the MI risk 
of individual PIs, recent indinavir was associated with 
increased MI risk compared with not recent exposure 
(RR: 1.46; 95% CI 1.08 to 1.95).52 67 Recent exposure to 
other PI regimens including atazanavir,52 67 lopinavir,52 67 
ritonavir,52 67 nelfinavir52 67 and saquinavir,52 67 were not 
found to be significantly associated with MI risk compared 
with not recent exposure (figure 6).
Risk of MI associated with any ART exposure
In terms of any treatment exposure, our meta-analysis did 
not find an association between exposure to ART and risk 
of MI compared with no exposure (online supplemen-
tary appendix figure A1).62 72 Based on the pooled results 
from six studies with data on NRTI exposure,8 11 13 52 63 68 
individuals receiving abacavir were more likely to have an 
MI compared with those who did not (RR: 1.58; 95% CI 
1.25 to 2.00). We found a similar association between 
didanosine exposure and MI risk (RR: 1.48; 95% CI 
1.16 to 1.90).13 52 68 No detectable association was found 
between exposure to tenofovir,52 68 zidovudine,13 52 stavu-
dine,13 52 68 emtricitabine52 68 and MI risk, based on our 
pooled results (online supplementary appendix figure 
A2). The meta-analysis of studies with data on NNRTI 
exposure did not find any evidence of an association 
between either efavirenz52 65 or nevirapine exposure,52 68 
and MI risk compared with no exposure (online supple-
mentary appendix figure A3). The pooled RR from four 
studies demonstrates that PI exposure is associated with 
an increase in the risk of MI events compared with no 
exposure to PI (RR: 1.49; 95% CI 1.16 to 1.91).3 6 61 63 
When the analysis was limited to two studies comparing 
recent PI exposure to no exposure,3 63 similar results were 
D
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Figure 3 Forest plot of the meta-analysis of the risk of MI associated with CD4 cell count and plasma viral load levels.
found (RR: 1.40; 95% CI 1.16 to 1.69 (data not shown)). 
For the individual PIs, there was no association between 
either atazanavir,52 64 66 68 saquinavir,52 68 or nelfinavir 
exposure,52 68 and MI risk, compared with no exposure 
(online supplementary appendix figure A4).
Risk of MI associated with cumulative ART exposure
With regards to cumulative treatment exposure, three eligible 
studies provided relevant data regarding the risk of MI 
and cumulative ART exposure.12 68 70 We found that cumu-
lative exposure to ART was associated with an increase 
in the risk of MI per year of exposure (RR: 1.12; 95% CI 
1.06 to 1.18) (online supplementary appendix figure 
A5). For exposure to NRTI regimens, we estimated an 
increase in MI risk per year of exposure to abacavir (RR: 
1.08; 95% CI 1.01 to 1.15) based on pooling data from 
two eligible studies.12 58 Similar to abacavir, cumulative 
zidovudine exposure was associated with an increase in 
MI risk per year of exposure (RR: 1.05; 95% CI 1.01 to 
1.10).11 13 We found no association between cumulative 
exposure to either didanosine,11 13 tenofovir,11 58 lamivu-
dine11 13 or stavudine,11 13 and MI risk per year of expo-
sure (online supplementary appendix figure A6). The 
overall RR suggests that cumulative NNRTI exposure as 
a class (RR: 1.02; 95% CI 0.97 to 1.08),59 70 72 or as indi-
vidual drugs (nevirapine and efavirenz),11 58 is not signifi-
cantly associated with increased risk of MI events per 
year of exposure (online supplementary appendix figure 
A7). Three eligible studies reported data assessing the 
risk of MI associated with cumulative exposure to PIs as 
a class.59 70 72 There was an increase in risk of MI per year 
of exposure to PIs (RR: 1.14; 95% CI 1.03 to 1.26). For 
individual drugs, cumulative exposure to lopinavir with 
ritonavir (RR: 1.19; 95% CI 1.03 to 1.39),11 58 but not nelfi-
navir,11 58 was found to be associated with increase in the 
risk of MI events per year of exposure (online supplemen-
tary appendix figure A8).
Sensitivity analyses
The strength and direction of the overall RR from the 
various meta-analyses remained robust in sensitivity anal-
yses where estimates reported using similar effect measures 
were pooled. For example, HIV+ individuals continued to 
have higher risk of MI events compared with uninfected 
individuals when pooled using either IRRs (overall effect: 
1.68; 95% CI 1.17 to 2.40) or HRs (overall effect: 1.75; 
95% CI 1.24 to 2.48) effect measures, compared with a 
RR of 1.73; 95% CI 1.44 to 2.08, obtained from pooling 
D
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Figure 4 Forest plot of the meta-analysis of the risk of MI associated with recent exposure to drugs of the NRTI class. 
NRTI,nucleoside reverse transcriptase inhibitors.
results reported using multiple relative effect measures 
(online supplementary appendix figure S2).
DIsCussIOn
This updated systematic review and meta-analysis 
assessing the risk of MI among people living with HIV 
reflects contemporary ART era and found the following: 
(1) HIV+ individuals have a greater risk of MI compared 
with uninfected individuals; and among HIV+ individuals, 
(2) low CD4 cell count (<200 cells/mm3) and high pVL 
(>100 000 copies/mL) are associated with increases in 
MI risk compared with higher CD4 or lower pVL, respec-
tively; (3) cumulative ART exposure is associated with a 
greater risk of MI per year of exposure; (4) among NRTIs, 
any type of exposure to abacavir; cumulative exposure to 
zidovudine; and recent exposure to either didanosine or 
lamivudine are significantly associated with higher risk of 
MI; (5) compared with no exposure, any or cumulative 
exposure to PIs as a class; cumulative exposure to lopinavir 
with ritonavir; and recent indinavir exposure were associ-
ated with higher risk of MI; (6) NNRTIs assessed either as 
a class or individually were not associated with increased 
MI risk.
Previous meta-analyses comparing CVD risk among 
HIV+ and uninfected individuals reported estimates for 
the association between HIV-seropositivity and MI (RR: 
1.79; 95% CI 1.54 to 2.08)19 or CVD (RR: 1.61; 95% CI 
1.43 to 1.81)20; risk that are similar to our findings for 
MI (RR: 1.73; 95% CI 1.44 to 2.08). As has been previ-
ously hypothesised,3 23 73–75 the probable mechanistic 
pathway through which HIV infection can induce MI may 
include a cascade of events involving chronic inflamma-
tion, immunodeficiency/CD4 cell depletion, endothe-
lial dysfunction, increased thrombosis and accelerated 
atherosclerosis that typically accompany both controlled 
and uncontrolled HIV disease. Relative to uninfected 
individuals and similar to what we found (RR: 1.80; 
95% CI 1.17 to 2.77), one of the previous meta-analysis 
also reported a higher risk of CVD among ART-treated 
individuals (RR: 2.00; 95% CI 1.70 to 2.37).20 We suspect 
that the higher MI risk among ART-treated HIV+ indi-
viduals may not necessarily be attributable to ART alone 
D
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Figure 5 Forest plot of the meta-analysis of the risk of MI associated with recent exposure to drugs of the NNRTI class. 
NNRTI,non-nucleoside reverse transcriptase inhibitor.
but rather to the combined effect from a host of factors 
including HIV itself, ART, and other comorbid risk factors 
which have been individually shown to contribute to MI 
risk.3 5 76 77 Furthermore, the risk associated with cumu-
lative ART exposure may be an index of the duration of 
HIV infection with its attendant inflammation, and not 
entirely the effect of cumulative exposure to ART per se.
Specific to abacavir and MI risk, our findings were 
similar to reports from a previous meta-analysis of obser-
vational studies of MI,16 but different from those of the 
meta-analysis of RCTs,17 18 or reports from aggregate clin-
ical trial studies,14 15 that suggested no risk associated with 
abacavir exposure. Although observational studies and 
RCT results regarding MI and CVD risk due to abacavir 
exposure among people living with HIV are largely at 
odds, the Simplification with Tenofovir-Emtricitabine 
or Abacavir-Lamivudine trial is the first RCT to support 
observational studies finding of increased risk of CVD with 
exposure to abacavir.78 Based on the available evidence to 
date, the controversy regarding the potential association 
between abacavir use and risk of MI will likely continue 
to plague the field of HIV therapeutics until such a time 
when definitive evidence describing the underlying mech-
anism can be produced.79 80 A sufficiently powered RCT 
with long follow-up and including real-world populations 
reflective of those typically seen clinically may be needed 
to fully resolve this clinical controversy.
Unlike our results where a class-level effect was evident 
for PIs, pooled aggregate clinical trial data after 1 year 
of treatment with four different PI-based regimens did 
not find evidence of an increased risk associated with PI 
compared with NRTI regimen (RR: 1.69; 95% CI 0.54 to 
7.48).81 When we pooled data of individual PIs separately, 
we did not observe the same ‘class-level’ results. In our 
analysis, different PI regimens carried different risks. For 
example, while recent indinavir and cumulative lopina-
vir-ritonavir exposure were associated with increased MI 
risk, nelfinavir or atazanavir did not appear to contribute 
to MI risk irrespective of the type of exposure data that 
were pooled.
In terms of the scope and design, our study differs from 
previous meta-analyses on this topic in several ways. First, 
we used an expanded search strategy that included more 
data sources and search of conference archives compared 
with prior meta-analyses.16–20 Second, as the association 
of HIV and ART may affect the risk of MI and other CVD 
events differently, we did not assess the risk of CVD in 
general, as was done in previous meta-analysis.20 Third, 
we have used more recent risk estimates from studies with 
longer follow-up such as the Data Collection on Adverse 
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Figure 6 Forest plot of the meta-analysis of the risk of MI associated with recent exposure to drugs of the protease inhibitor 
class.
Events of Anti-HIV Drugs (D:A:D) study. Fourth, we have 
included studies published between 2000 and 2017 with 
reported data from the post-ART era. The historical nature 
of some of the studies included in previous meta-analysis 
may have limited their relevance in contemporary times. 
Finally, this systematic review analysed several additional 
drug exposure comparisons and clinical measures (eg, 
CD4 cell count, pVL) in relation to MI risk that had not 
been previously examined.
There are several important considerations that should 
be taken into account in the interpretation of the results 
of this study. Accurate characterisation of the risk of MI 
and CVD outcomes in general may be confounded by 
a number of factors that may have affected our conclu-
sions. The first concern has to do with the differences in 
the risk factors, drug exposure, HIV-related variables, or 
population considered in the included studies. Indeed, 
no two studies of HIV+ individuals from different under-
lying populations can have participants with the same 
exact demographic, clinical and drug exposure profile—
all of which play a role in overall health outcomes. Given 
that studies typically included in a global meta-analysis 
such as ours do not come from the same underlying 
source population, we acknowledge that there may be 
some differences in the population distribution in the 
included studies (eg, in the distribution by age, sex, 
disease stage, medication profile/history) that we were 
unable to account for. A second concern relates to 
the variability in the quality and design features of the 
included studies, which may have influenced the results 
of the meta-analyses and thus the conclusions drawn. 
Although the majority of included studies were cohort-
based (90%), almost one half (47%) were retrospective 
in nature and did not adequately report how the expo-
sure or outcome was ascertained including whether an 
adjudication protocol was applied in the ascertainment of 
MIs. It has been shown that the application of an adjudi-
cation protocol in the study of MI and other CVD events 
is important to ensuring accurate identification of events 
as relying only on administrative diagnostic codes could 
result in misclassification.82 While some studies retrospec-
tively assessed MI and relied on International Classifi-
cation of Diseases codes alone—something that is quite 
common in large epidemiological studies of MI,76 others 
D
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followed participants over time and prospectively assessed 
and validated the MI events. It is unclear how differences 
in MI definition across studies may have affected our 
results although in two studies from the same underlying 
population (Veterans Ageing Cohort Study) that used 
similar but not the same definitions for MI,3 83 the RR 
differed slightly: 1.48 (95% CI 1.27 to 1.72)3 versus 1.76 
(95% CI 1.49 to 2.07).83 Regarding studies that quantified 
the risk of MI associated with HIV infection, the available 
evidence based on the included studies all point in the 
same direction suggesting an increase in MI risk. However, 
we noted some variability in the design and quality of the 
studies, something that may have contributed in part to 
the observed heterogeneity. For example, three studies 
did not provide sufficient information on the exposure 
or outcome ascertainment in the studies.52 56 69 Further-
more, the appropriateness of the HIV-uninfected group 
used for comparison purposes is critical in the assess-
ment of MI risk associated with HIV infection; an issue 
that has been extensively reviewed elsewhere.84 While 
some studies made this comparison using an HIV-unin-
fected group, other studies used the general population 
group for comparison. In sensitivity analysis, the overall 
RR of MI associated with HIV infection was reduced when 
we included in the meta-analysis two additional studies 
involving a ‘general population’ comparison group,42 43 
therefore highlighting the importance of using an appro-
priate control group.
Another potential concern relates to differences 
in the extent to which key confounding factors were 
adjusted for in the individual analysis contributing to the 
meta-analysis. For example, some studies lacked data on 
smoking—an important risk factor for CVD in general, 
and therefore did not account for it in the analyses.52 60 65 
In this regard, we noted that the included studies did not 
consistently control for the exact same set of confounders 
which may have undermined their internal validity and 
explained some of the differences in the effect measures 
from the individual studies. There is also the potential 
for residual, unmeasured confounding given the obser-
vational nature of the included studies. Therefore, 
heterogeneity arising from differences in study design 
or other quality features may have influenced the results 
and thus the overall conclusions drawn. Although we 
observed heterogeneity across results of studies included 
in some of the meta-analyses, this is a common limitation 
in meta-analysis especially those involving observational 
studies.44 Our a priori choice of employing the random-ef-
fects modelling strategy was driven in part by this 
expected variability among studies.85 Furthermore, our 
study combined results presented using several different 
relative effect measures with the assumption that these 
represent approximately the same numerical value.31–36 
In sensitivity analyses, we did not find any evidence of bias 
in our pooled estimates, as these did not differ impor-
tantly from the pooled estimates we obtained when we 
combined studies reporting results using the same effect 
measure. Moreover, we reached comparable conclusions 
with previous meta-analyses that combined,19 or did not 
combine HR estimates with OR, and RR.16
Also, some of the meta-analyses in our study such as 
those examining the risk of MI in relation to CD4, pVL 
or use of specific ARV regimens were based on a small 
number of studies (only 2–3 studies), which is a serious 
limitation. It is important to also consider this point in the 
interpretation of these specific findings. We acknowledge 
that the results from such meta-analyses could have been 
strengthened with the inclusion of additional eligible 
studies. Nevertheless, in the absence of sufficient number 
of studies examining these relationships, our results could 
be viewed as the best available evidence summarising the 
risk of MI associated with CD4, pVL or use of specific ARV 
regimens among people living with HIV.
Given the foregoing discussion in relation to the design 
and quality aspects of the included studies as well as 
issues of sufficiency of available studies examining several 
potential associations with MI risk, additional rigorously 
conducted studies with extensive confounding factor 
stratification/adjustment are needed to further confirm 
our findings. Furthermore, considering that the majority 
of the studies on this topic are carried out in North 
America and Europe, our study highlights the need 
for more research to be conducted in resource limited 
settings where most people living with HIV reside.
COnClusIOns
In summary, this updated systematic review and 
meta-analysis suggests that HIV infection, ART use in 
general including exposure to specific ART class (eg, PIs) 
and regimen (eg, abacavir) are associated with increased 
risk of MI. These findings should be interpreted in light 
of the key considerations that we have highlighted in 
this review. We found the totality of the evidence for an 
association between HIV infection and MI to be compel-
ling. With respect to ART and MI risk, HIV treatment 
strategies should certainly consider cardiovascular risk 
factors including exposure to particular ART drugs as 
part of patient-tailored care. However, given what we 
currently know about ART’s effectiveness, the benefits 
of ART for the treatment of HIV infection in terms of 
viral suppression and immune reconstitution should be 
balanced against its potential unfavourable impact on MI. 
Specific to abacavir and MI risk where there is conflicting 
evidence between observational studies and RCTs, addi-
tional rigorously conducted studies in real-world popula-
tions are needed to definitively substantiate our findings 
and strengthen the existing evidence on this topic. Given 
the multiple potential contributory and mechanistic 
pathways to developing MI among HIV+ individuals and 
the complexity/feasibility of designing a large enough 
study to completely tease apart the potential contribu-
tions of each of the factors believed to increase the risk 
of MI, managing known modifiable risk factors for CVD 
outcomes (eg, smoking) through behavioural/lifestyle 
interventions, would be an excellent first step in reducing 
D
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the incidence and risk of MI among people living with 
HIV.
Author affiliations
1Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, 
Canada
2Faculty of Health, York University, Toronto, ON, Canada
3British Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada
4George & Fay Yee Centre for Healthcare Innovation, University of Manitoba, 
Winnipeg, Manitoba, Canada
5Department of Occupational Science and Occupational Therapy, Faculty of 
Medicine, University of British Columbia, Burnaby, British Columbia, Canada
6Department of Clinical Epidemiology and Biostatistics, McMaster University, 
Hamilton, Ontario, Canada
7Healthy Heart Program, St. Paul's Hospital, Providence Health Care, Vancouver, 
British Columbia, Canada
8Division of Cardiology, Department of Medicine, University of British Columbia, 
Vancouver, British Columbia, Canada
9School of Public Health, University of Alberta, Edmonton, Alberta, Canada
10Department of Medicine, University of British Columbia, Vancouver, British 
Columbia, Canada
Acknowledgements We thank Simon Fraser University library staff for the 
assistance provided during the search strategy development.
Contributors OE, MWH, SAL, JSGM and RSH conceived and designed the study. 
OE, GB and RSH acquired the data. OE performed the statistical analysis with input 
from CHG, CF-V and EJM. OE, GB, CHG, MWH, SAL, MB, SG, CF-V, AA, EJM, JSGM 
and RSH contributed to the interpretation of the data. OE drafted the manuscript. 
OE, GB, CHG, MWH, SAL, MB, SG, CF-V, AA, EJM, JSGM and RSH reviewed the 
manuscript critically for important intellectual content and approved the final 
version submitted for publication.
Funding The authors have not declared a specific grant for this research from any 
funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement All data and materials used in this research are 
available in Medline/PubMed. References have been provided.
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non-commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the use 
is non-commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
rEFErEnCEs
 1. Antiretroviral Therapy Cohort Collaboration. Causes of death in 
HIV-1-infected patients treated with antiretroviral therapy, 1996-
2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis 
2010;50:1387–96.
 2. Smith CJ, Ryom L, Weber R, et al. Trends in underlying causes of 
death in people with HIV from 1999 to 2011 (D:A:D): a multicohort 
collaboration. The Lancet 2014;384:241–8.
 3. Freiberg MS, Chang C-CH, Kuller LH, et al. Hiv infection and the risk 
of acute myocardial infarction. JAMA Intern Med 2013;173:614–22.
 4. Marcus JL, Leyden WA, Chao CR, et al. Hiv infection and incidence 
of ischemic stroke. AIDS 2014;28:1911–9.
 5. Friis-Møller N, Sabin CA, Weber R, et al. Combination antiretroviral 
therapy and the risk of myocardial infarction. N Engl J Med 
2003;349:1993–2003.
 6. Mary-Krause M, Cotte L, Simon A, et al. Increased risk of myocardial 
infarction with duration of protease inhibitor therapy in HIV-infected 
men. AIDS 2003;17:2479–86.
 7. Friis-Møller N, Reiss P, Sabin CA, et al. Class of antiretroviral 
drugs and the risk of myocardial infarction. N Engl J Med 
2007;356:1723–35.
 8. Obel N, Farkas DK, Kronborg G, et al. Abacavir and risk of 
myocardial infarction in HIV-infected patients on highly active 
antiretroviral therapy: a population-based nationwide cohort study. 
HIV Med 2010;11:130–6.
 9. Strategies for Management of Anti-Retroviral Therapy/INSIGHT, DAD 
Study Groups. Use of nucleoside reverse transcriptase inhibitors 
and risk of myocardial infarction in HIV-infected patients. AIDS 
2008;22:F17–F24.
 10. Bozzette SA, Ake CF, Tam HK, et al. Long-Term survival and 
serious cardiovascular events in HIV-infected patients treated with 
highly active antiretroviral therapy. J Acquir Immune Defic Syndr 
2008;47:338–41.
 11. Lang S, Mary-Krause M, Cotte L, et al. Impact of individual 
antiretroviral drugs on the risk of myocardial infarction in human 
immunodeficiency virus-infected patients: a case-control study 
nested within the French Hospital database on HIV ANRS cohort 
CO4. Arch Intern Med 2010a;170:1228–38.
 12. Bedimo RJ, Westfall AO, Drechsler H, et al. Abacavir use and risk of 
acute myocardial infarction and cerebrovascular events in the highly 
active antiretroviral therapy era. Clin Infect Dis 2011;53:84–91.
 13. Sabin CA, Worm SW, Weber R, et al. Use of nucleoside reverse 
transcriptase inhibitors and risk of myocardial infarction in HIV-
infected patients enrolled in the D:A:D study: a multi-cohort 
collaboration. Lancet 2008a;371:1417–26.
 14. Brothers CH, Hernandez JE, Cutrell AG, et al. Risk of myocardial 
infarction and abacavir therapy: no increased risk across 52 
GlaxoSmithKline-sponsored clinical trials in adult subjects. J Acquir 
Immune Defic Syndr 2009;51:20–8.
 15. Ribaudo HJ, Benson CA, Zheng Y, et al. No risk of myocardial 
infarction associated with initial antiretroviral treatment containing 
abacavir: short and long-term results from ACTG A5001/ALLRT. Clin 
Infect Dis 2011;52:929–40.
 16. Bavinger C, Bendavid E, Niehaus K, et al. Risk of cardiovascular 
disease from antiretroviral therapy for HIV: a systematic review. PLoS 
One 2013;8:e59551.
 17. Ding X, Andraca-Carrera E, Cooper C, et al. No association of 
abacavir use with myocardial infarction: findings of an FDA meta-
analysis. J Acquir Immune Defic Syndr 2012;61:441–7.
 18. Cruciani M, Zanichelli V, Serpelloni G, et al. Abacavir use and 
cardiovascular disease events: a meta-analysis of published and 
unpublished data. AIDS 2011;25:1993–2004.
 19. Shah ASV, Stelzle D, Lee KK, et al. Global burden of atherosclerotic 
cardiovascular disease in people living with the human 
immunodeficiency virus: a systematic review and meta-analysis. 
Circulation 2018
 20. Islam FM, Wu J, Jansson J, et al. Relative risk of cardiovascular 
disease among people living with HIV: a systematic review and meta-
analysis. HIV Med 2012;13:n/a–68.
 21. Neaton JD. HIV and cardiovascular disease: comment on Islam et al. 
HIV Med 2013;14:517–8.
 22. Iloeje UH, Yuan Y, L'Italien G, et al. Protease inhibitor exposure and 
increased risk of cardiovascular disease in HIV-infected patients. HIV 
Med 2005;6:37–44.
 23. Lichtenstein KA, Armon C, Buchacz K, et al. Low CD4 + T Cell 
Count Is a Risk Factor for Cardiovascular Disease Events in the HIV 
Outpatient Study. Clin Infect Dis 2010;51:435–47.
 24. Choi AI, Vittinghoff E, Deeks SG, et al. Cardiovascular risks 
associated with abacavir and tenofovir exposure in HIV-infected 
persons. AIDS 2011;25:1289–98.
 25. Klein MB, Xiao Y, Abrahamowicz M, et al. Re-assessing the 
cardiovascular risk of abacavir in the Swiss HIV Cohort Study 
(SHCS) using a flexible marginal structural model [ICPE Abstract 
396]. In: Abstracts of the 29th International Conference on 
Pharmacoepidemiology & Therapeutic Risk Management. 
Pharmacoepidemiol Drug Saf 2013;22:193–4.
 26. Widimsky P, Coram R, Abou-Chebl A. Reperfusion therapy of acute 
ischaemic stroke and acute myocardial infarction: similarities and 
differences. Eur Heart J 2014;35:147–55.
 27. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for 
systematic reviews and meta-analyses: the PRISMA statement. Ann 
Intern Med 2009;151:264–9.
 28. Eyawo O, Brockman G, Lear S, et al. Risk of cardiovascular disease 
events among HIV-positive individuals compared to HIV-negative 
individuals: a systematic review and meta-analysis (number: 
CRD42014012977). Inte Prospect Regist Syst Rev 2014.
 29. Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa scale 
(NOS) for assessing the quality of nonrandomised studies in meta-
analyses, 2018. Available: http://www. ohri. ca/ programs/ clinical_ 
epidemiology/ oxford. asp [Accessed 17 January 2019].
 30. Landis JR, Koch GG. The measurement of observer agreement for 
categorical data. Biometrics 1977;33:159–74.
 31. Symons MJ, Moore DT. Hazard rate ratio and prospective 
epidemiological studies. J Clin Epidemiol 2002;55:893–9.
D





ber 6, 2019 at Sim




pen: first published as 10.1136/bmjopen-2018-025874 on 24 September 2019. Downloaded from 
12 Eyawo O, et al. BMJ Open 2019;9:e025874. doi:10.1136/bmjopen-2018-025874
Open access 
 32. Sedgwick P. Hazards and hazard ratios. BMJ 2012;345:e5980.
 33. Hernán MA. The hazards of hazard ratios. Epidemiology 
2010;21:13–15.
 34. McCullagh P, Nelder JA. Chapter 13: models for survival data. In: 
McCullagh P, Nelder JA, eds. Generalized linear models. 2nd ed. 
London, New York: Chapman & Hall/CRC, 1989: 419–31.
 35. Laird N, Olivier D. Covariance analysis of censored survival 
data using log-linear analysis techniques. J Am Stat Assoc 
1981;76:231–40.
 36. Symons MJ, Taulbee JD. Practical considerations for approximating 
relative risk by the standardized mortality ratio. J Occup Environ Med 
1981;23:413–6.
 37. Fernández MDM, Saulyte J, Inskip HM, et al. Premenstrual syndrome 
and alcohol consumption: a systematic review and meta-analysis. 
BMJ Open 2018;8:e019490.
 38. Byrne AL, Marais BJ, Mitnick CD, et al. Tuberculosis and 
chronic respiratory disease: a systematic review. Int J Infect Dis 
2015;32:138–46.
 39. Beckett MW, Ardern CI, Rotondi MA. A meta-analysis of prospective 
studies on the role of physical activity and the prevention of 
Alzheimer’s disease in older adults. BMC Geriatr 2015;15:9.
 40. Bateson D, Butcher BE, Donovan C, et al. Risk of venous 
thromboembolism in women taking the combined oral contraceptive: 
a systematic review and meta-analysis. Aust Fam Physician 
2016;45:59–64.
 41. DerSimonian R, Laird N. Meta-Analysis in clinical trials. Control Clin 
Trials 1986;7:177–88.
 42. Drozd DR, Kitahata MM, Althoff KN, et al. Increased risk of 
myocardial infarction in HIV-infected individuals in North America 
compared with the general population. J Acquir Immune Defic Syndr 
2017;75:568–76.
 43. Lang S, Mary-Krause M, Cotte L, et al. Increased risk of myocardial 
infarction in HIV-infected patients in France, relative to the general 
population. AIDS 2010b;24:1228–30.
 44. Mills EJ, Jansen JP, Kanters S. Heterogeneity in meta-analysis of 
FDG-PET studies to diagnose lung cancer. JAMA 2015;313.
 45. Higgins JPTet al. Measuring inconsistency in meta-analyses. BMJ 
2003;327:557–60.
 46. Higgins J, Green S. Cochrane Handbook for Systematic Reviews of 
Interventions, Version 5.1.0 [updated March 2011]: The Cochrane 
Collaboration,, 2011. Available: http://www. cochrane. org/ handbook 
[Accessed 27 July 2017].
 47. Egger M, Smith GD, Schneider M, et al. Bias in meta-analysis 
detected by a simple, graphical test. BMJ 1997;315:629–34.
 48. Ioannidis JPA, Trikalinos TA. The appropriateness of asymmetry tests 
for publication bias in meta-analyses: a large survey. Can Med Assoc 
J 2007;176:1091–6.
 49. Lau J, Ioannidis JPA, Terrin N, et al. The case of the misleading 
funnel plot. BMJ 2006;333:597–600.
 50. Viechtbauer W. Conducting meta-analyses in R with the metafor 
package. J Stat Softw 2010;36:1–48.
 51. Lang S, Mary-Krause M, Simon A, et al. Hiv replication and immune 
status are independent predictors of the risk of myocardial infarction 
in HIV-infected individuals. Clin Infect Dis 2012;55:600–7.
 52. Durand M, Sheehy O, Baril J-G, et al. Association between HIV 
infection, antiretroviral therapy, and risk of acute myocardial 
infarction: a cohort and nested case-control study using Québec's 
public health insurance database. J Acquir Immune Defic Syndr 
2011;57:245–53.
 53. Sabin CA, Reiss P, Ryom L, et al. Is there continued evidence for an 
association between abacavir usage and myocardial infarction risk in 
individuals with HIV? a cohort collaboration. BMC Med 2016;14:61.
 54. Salinas JL, Rentsch C, Marconi VC, et al. Baseline, Time-Updated, 
and cumulative HIV care metrics for predicting acute myocardial 
infarction and all-cause mortality. Clin Infect Dis. 2016;63:1423–30.
 55. Palella FJ, Althoff KN, Moore R, et al. Abacavir use and risk 
for myocardial infarction in the NA-ACCORD [CROI Abstract 
749LB]. In Special Issue: Abstracts From the 2015 Conference 
on Retroviruses and Opportunistic Infections. Top Antivir Med 
2015;23:335–6.
 56. Rasmussen LD, May MT, Kronborg G, et al. Time trends for risk 
of severe age-related diseases in individuals with and without HIV 
infection in Denmark: a nationwide population-based cohort study. 
The Lancet HIV 2015;2:e288–98.
 57. Drozd DR, Nance RM, Delaney JAC, et al. Lower CD4 count and 
higher viral load are associated with increased risk of myocardial 
infarction [CROI abstract 739]. In Special Issue: Abstracts From the 
2014 Conference on Retroviruses and Opportunistic Infections. Top 
Antivir Med 2014;22:377.
 58. Worm SW, Sabin C, Weber R, et al. Risk of myocardial infarction in 
patients with HIV infection exposed to specific individual antiretroviral 
drugs from the 3 major drug classes: the data collection on adverse 
events of anti-HIV drugs (D:A:D) study. J Infect Dis 2010;201:318–30.
 59. Sabin CA, d'Arminio Monforte A, Friis-Moller N, et al. Changes over 
time in risk factors for cardiovascular disease and use of lipid-
lowering drugs in HIV-infected individuals and impact on myocardial 
infarction. Clin Infect Dis 2008b;46:1101–10.
 60. Obel N, Thomsen HF, Kronborg G, et al. Ischemic heart disease in 
HIV-infected and HIV-uninfected individuals: a population-based 
cohort study. Clin Infect Dis 2007;44:1625–31.
 61. Holmberg SD, Moorman AC, Williamson JM, et al. Protease inhibitors 
and cardiovascular outcomes in patients with HIV-1. The Lancet 
2002;360:1747–8.
 62. Rickerts V, Brodt H, Staszewski S, et al. Incidence of myocardial 
infarctions in HIV-infected patients between 1983 and 1998: the 
Frankfurt HIV-cohort study. Eur J Med Res 2000;5:329–33.
 63. Carman WJ, Bowlin S, McAfee AT. Human immunodeficiency 
(HIV) therapy and cardiovascular (CV) events [ICPE Abstract 
323]. In: Abstracts from the 27th International Conference on 
Pharmacoepidemiology & Therapeutic Risk Management. 
Pharmacoepidemiol Drug Saf 2011;20.
 64. LaFleur J, Bress AP, Rosenblatt L, et al. Cardiovascular outcomes 
among HIV-infected veterans receiving atazanavir. AIDS 
2017;31:2095–106.
 65. Rosenblatt L, Farr AM, Johnston SS, et al. Risk of cardiovascular 
events among patients initiating efavirenz-containing versus 
Efavirenz-Free antiretroviral regimens. Open Forum Infect Dis 
2016a;3:ofw061.
 66. Rosenblatt L, Farr AM, Nkhoma ET, et al. Risk of cardiovascular 
events among patients with HIV treated with atazanavir-
containing regimens: a retrospective cohort study. BMC Infect Dis 
2016b;16:492.
 67. Desai M, Joyce V, Bendavid E, et al. Risk of cardiovascular events 
associated with current exposure to HIV antiretroviral therapies in a 
US veteran population. Clin Infect Dis 2015;61:445–52.
 68. Triant VA, Regan S, Lee H, et al. Association of immunologic and 
virologic factors with myocardial infarction rates in a US healthcare 
system. J Acquir Immune Defic Syndr 2010;55:615–9.
 69. Triant VA, Meigs JB, Grinspoon SK. Association of C-reactive protein 
and HIV infection with acute myocardial infarction. J Acquir Immune 
Defic Syndr 2009;51:268–73.
 70. Kwong GPS, Ghani AC, Rode RA, et al. Comparison of the risks of 
atherosclerotic events versus death from other causes associated 
with antiretroviral use. AIDS 2006;20:1941–50.
 71. Klein DB, Leyden WA, Xu L, et al. Declining relative risk for 
myocardial infarction among HIV-positive compared with 
HIV-negative individuals with access to care. Clin Infect Dis 
2015;60:1278–80.
 72. Silverberg MJ, Leyden WA, Xu L, et al. Immunodeficiency and risk of 
myocardial infarction among HIV-positive individuals with access to 
care. J Acquir Immune Defic Syndr 2014;65:160–6.
 73. Hansson GK, Inflammation HGK. Inflammation, atherosclerosis, and 
coronary artery disease. N Engl J Med 2005;352:1685–95.
 74. Lo J, Plutzky J. The biology of atherosclerosis: general paradigms 
and distinct pathogenic mechanisms among HIV-infected patients. J 
Infect Dis 2012;205(Suppl_3):S368–S374.
 75. Cerrato E, Calcagno A, D'Ascenzo F, et al. Cardiovascular disease 
in HIV patients: from bench to bedside and backwards. Open Heart 
2015;2:e000174.
 76. Triant VA, Lee H, Hadigan C, et al. Increased acute myocardial 
infarction rates and cardiovascular risk factors among patients with 
human immunodeficiency virus disease. J Clin Endocrinol Metab 
2007;92:2506–12.
 77. Calza L, Manfredi R, Verucchi G. Myocardial infarction risk in 
HIV-infected patients: epidemiology, pathogenesis, and clinical 
management. AIDS 2010;24:789–802.
 78. Martin A, Bloch M, Amin J, et al. Simplification of antiretroviral 
therapy with Tenofovir‐Emtricitabine or Abacavir‐Lamivudine: a 
randomized, 96‐Week trial. Clin Infect Dis 2009;49:1591–601.
 79. Alvarez A, Orden S, Andujar I, et al. Cardiovascular toxicity of 
abacavir: a clinical controversy in need of a pharmacological 
explanation. AIDS 2017;31:1781–95.
 80. Llibre JM, Hill A. Abacavir and cardiovascular disease: a critical look 
at the data. Antiviral Res 2016;132:116–21.
 81. Coplan PM, Nikas A, Japour A, et al. Incidence of myocardial 
infarction in randomized clinical trials of protease inhibitor-based 
antiretroviral therapy: an analysis of four different protease inhibitors. 
AIDS Res Hum Retroviruses 2003;19:449–55.
 82. Crane HM, Heckbert SR, Drozd DR, et al. Lessons learned 
from the design and implementation of myocardial infarction 
adjudication tailored for HIV clinical cohorts. Am J Epidemiol 
2014;179:996–1005.
D





ber 6, 2019 at Sim




pen: first published as 10.1136/bmjopen-2018-025874 on 24 September 2019. Downloaded from 
13Eyawo O, et al. BMJ Open 2019;9:e025874. doi:10.1136/bmjopen-2018-025874
Open access
 83. Althoff KN, McGinnis KA, Wyatt CM, et al. Comparison of risk and 
age at diagnosis of myocardial infarction, end-stage renal disease, 
and non-AIDS-defining cancer in HIV-infected versus uninfected 
adults. Clin Infect Dis 2015;60:627–38.
 84. Althoff KN, Gange SJ. A critical epidemiological review of 
cardiovascular disease risk in HIV-infected adults: the importance of 
the HIV-uninfected comparison group, confounding, and competing 
risks. HIV Med 2013;14:191–2.
 85. Hedges LV, Vevea JL. Fixed- and random-effects models in meta-
analysis. Psychol Methods 1998;3:486–504.
D





ber 6, 2019 at Sim




pen: first published as 10.1136/bmjopen-2018-025874 on 24 September 2019. Downloaded from 
